What's New

Inagene has partnered with fellow Canadian health-tech company Granville Biomedical to add Canadian developed and researched medical grade swabs to...

Only one in three people prescribed antidepressants or pain medication find an effective treatment on the first try.  Not finding the right medication can have dire consequences. The study recruited 50 patients being treated for chronic pain and mental health conditions.

Meet "Richard"   “Richard” is one of the six million Canadians with a story to tell about living with chronic pain and the impact on his mental he...

Inagene CEO Nancy White is joined by Jane Sarasohn-Kahn to discuss post-pandemic health trends including health economics, the echo-pandemic and technologies that are shaping a holistic approach to care.

Calian Group Ltd., one of Canada's largest national health services organizations, supported a ground-breaking pilot study by Inagene Diagnostics in late 2020 to evaluate the “real-life” value of pharmacogenetic testing in optimizing the treatment of chronic pain and mental health conditions. Fifty Canadians who were being treated for chronic pain and concurrent mental health conditions were recruited from a busy clinic in PEI for the study in late 2020 to evaluate the impact pharmacogenetic testing could have on treatment, and on the time and cost burden involved in trialing different medications.  The results were compelling and validated outcomes from previous studies.

On May 13th, Global News Health Matters segment featured Inagene and Pharmacogenetic testing (PGx), helping to bring awareness to how this new science is revolutionizing the way drugs are prescribed, and empowering Canadians living with mental health conditions to move beyond the antiquated “trial and error” method of finding the right treatment and start feeling better, sooner.

Inagene and dnaPower Launch the fourth Episode of The Healthy Helix; a series supporting education, innovation and information across the healthcare landscape.

Inagene Diagnostics raising awareness about the power of personalized pain management for all Canadians as featured on MONTRÉAL enSANTÉ magazine.

Inagene sponsors an accredited webinar with expert pharmacist John Papastergious at the Pharmacy U Vancouver Conference this past November.

Inagene Diagnostics, in partnership with dnaPower, explores health through the lens of genetics, personalized medicine and prevention to help individuals make the best decisions to live their healthiest lives in the context of COVID-19.

A powerful tool for those looking to do more to protect their health in the event they are hospitalized for COVID 19 (or any other medical condition).

Inagene Diagnostics in partnership with dnaPower, take a dive deep to inform consumers how their test results can be transformative in achieving their best health